Association of MammaPrint index and 3-year outcome of patients with HR+HER2-early-stage breast cancer treated with chemotherapy with or without anthracycline

被引：0
|
作者：
O'Shaughnessy, Joyce
Graham, Cathy Lynne
Whitworth, Pat
Beitsch, Peter D.
Osborne, Cynthia R. C.
Rahman, Rakhshanda Layeequr
Brown, Eric Allen
Gold, Linsey P.
Johnson, Nathalie Mcdowell
Brufsky, Adam
Ramaswamy, Harshini
Stivers, Nicole
Menicucci, Andrea
Audeh, M. William
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[2] Emory Univ, Atlanta, GA USA
[3] Nashville Breast Ctr, Nashville, TN USA
[4] Dallas Surg Grp, Dallas, TX USA
[5] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX USA
[6] Comprehens Breast Care, Troy, MI USA
[7] Legacy Hlth Syst, Portland, OR USA
[8] Univ Pittsburgh, Pittsburgh, PA USA
[9] Agendia Inc, Med Affairs, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
511
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MammaPrint and BluePrint identify racial disparities among women with HR+HER2-early-stage breast cancer
    Reid, Sonya
    Shu, Xiao-Ou
    Venton, Lindsay
    Haan, Josien
    Menicucci, Andrea
    Dauer, Patricia
    Audeh, William
    Pal, Tuya
    CANCER RESEARCH, 2024, 84 (09)
  • [2] MammaPrint index predicts neoadjuvant chemosensitivity in patients with HR+HER2-early-stage breast cancer in the real-world evidence FLEX study
    O'Shaughnessy, Joyce
    Pusztai, Lajos
    Graham, Cathy
    Whitworth, Pat
    Beitsch, Peter
    Osborne, Cynthia
    Rahman, Rakhshanda
    Menicucci, Andrea
    Audeh, William
    CANCER RESEARCH, 2024, 84 (09)
  • [3] MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2-breast cancer in NBRST.
    Beitsch, Peter D.
    Pellicane, James V.
    Pusztai, Lajos
    Baron, Paul
    Cobain, Erin Frances
    Murray, Mary K.
    Ashikari, Andrew
    Kelemen, Pond R.
    Mislowsky, Angela Marie
    Barone, Julie
    Cowan, Kenneth H.
    Rahman, Rakhshanda Layeequr
    Dooley, William C.
    Menicucci, Andrea
    Finn, Christine
    Audeh, M. William William
    Whitworth, Pat W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Clinical outcome for HR+/HER2-stage IV breast cancer patients
    Goto, Risa
    Aruga, Tomoyuki
    Honda, Yahoi
    Idera, Nami
    Horiguchi, Kazumi
    Miyamoto, Hiromi
    Yamashita, Toshinari
    Horiguchi, Shinnichiro
    Kuroi, Katsumasa
    ANNALS OF ONCOLOGY, 2015, 26 : 142 - 142
  • [5] A two year comparison of quality of life for early stage breast cancer patients treated with whole breast IMRT with and without chemotherapy
    Boyea, G.
    Flynn, C.
    Balasubramaniam, M.
    Wallace, M.
    Vicini, F.
    Martinez, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S196 - S196
  • [6] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
  • [7] Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2-breast cancer
    Coelho, Joao Queiros
    Lau, Beatriz
    Pichel, Rita
    Guerra, Laura
    Miranda, Hugo
    Romao, Raquel
    Sousa, Maria Joao
    Goncalves, Fernando
    Simoes, Joana
    Azevedo, Sergio Xavier
    Araujo, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [8] CLINICAL OUTCOME OF ENDOCRINE THERAPY FOR HR + /HER2-STAGE IV BREAST CANCER PATIENTS
    Goto, Risa
    Aruga, Tomoyuki
    Honda, Yayoi
    Idera, Nami
    Kitagawa, Dai
    Horiguchi, Kazumi
    Miyamoto, Hiromi
    Yamashita, Toshinari
    Kuroi, Katsumasa
    ANNALS OF ONCOLOGY, 2014, 25
  • [9] Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Mukku, R. B.
    Verma, S.
    Liu, J.
    Steingart, R.
    Hudis, C.
    Yu, A. F.
    Dang, C.
    CANCER RESEARCH, 2016, 76
  • [10] Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Mukku, R. B.
    Verma, S.
    Liu, J.
    Steingart, R.
    Hudis, C.
    Yu, A. F.
    Dang, C.
    CANCER RESEARCH, 2016, 76
12345